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The incidence of cutaneous melanoma has approximately doubled
each decade for the last 50 years (Koh, 1991). It has been assumed
that by the year 2000 one in 75 persons in the US will be affected
by this type of skin cancer (Robinson et al, 1997). Cancer develop-
ment is a complex, multistep process characterized by the ab-
normal activation of cellular proto-oncogenes and the loss of
function of tumour suppressor genes (Vogelstein and Kinzler,
1993). A central role in the regulation of cell growth and differen-
tiation is assigned to the c-myc proto-oncogene (Meichle et al,
1992). The c-myc gene is located to 8q24 (Taub et al, 1982) and it
encodes a 439 amino acid phosphoprotein of 62 kDa with a
predominantly nuclear localization (Cole, 1986). After the detec-
tion of an amplified c-myc gene locus in different human cell lines
(Collins and Groudine, 1982; Little et al, 1983) oncogenic activa-
tion of the c-myc gene through amplification has been demon-
strated. C-myc expression levels have been suggested to be of
prognostic importance in several types of cancer (Garte, 1993).
Contradictory results concerning the influence of c-myc expres-
sion on melanoma formation have been published, either arguing
for a correlation of tumour progression with c-myc overexpression
(Ross and Wilson, 1998) or for a lack of prognostic significance
(Boni et al, 1998). Abnormalities of chromosome 8 have rarely
been reported in cutaneous malignant melanoma (Pedersen et al,
1986; Ozisik et al, 1994). In contrast, additional copies of 8q are
frequent in uveal melanoma (Horsman et al, 1990; Prescher et al,
1990), and the presence of additional 8q copies is associated with
reduced survival (Sisley et al, 1997). 
Interphase FISH (Cremer et al, 1986) is useful for the detection
of numerical chromosomal abnormalities and genetic alterations in
solid tumours including malignant melanomas, which are often
difficult to analyse by conventional cytogenetics. In this study we
enumerated and compared c-myc and chromosome 8 copy numbers
within interphase nuclei (Hopman et al, 1994; Visscher et al, 1997)
of normal skin, benign nevi, cutaneous primary and advanced
malignant melanomas and corresponding safety margins. 
Additionally, we analysed metaphase spreads from 7 melanoma
cell lines with probes for c-myc, centromere of chromosome 8,
and whole chromosome 8 (Pinkel et al, 1986; Lichter et al, 1991;
Bar-Am et al, 1992). 
MATERIALS AND METHODS 
62 cases including 8 primary cutaneous melanomas, 33 metastases
of cutaneous malignant melanomas (13 lymph node and 20 distant
cutaneous melanoma metastases), 12 nevi, 7 safety margins
(surrounding macroscopically normal tissue between 1 and 3 cm
from the margin of the primary tumours) and 2 samples of normal
skin were collected from the Department of Dermatology at 
the University of Ulm, Germany. Touch preparations were
prepared from unfixed tissue. Slides were fixed immediately in 4%
Extra c-myc oncogene copies in high risk cutaneous
malignant melanoma and melanoma metastases 
GM Kraehn* 1,2, J Utikal* 1, M Udart1, KM Greulich1,3, G Bezold1, P Kaskel1, U Leiter1 and RU Peter1
1Department of Dermatology, University of Ulm, Ulm, Germany; 2Department of Pharmacology, University of California, San Diego, La Jolla, USA; 
3Division of Carcinogenesis, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany 
Summary Amplification and overexpression of the c-myc gene have been associated with neoplastic transformation in a plethora of
malignant tumours. We applied interphase fluorescence in situ hybridization (FISH) with a locus-specific probe for the c-myc gene (8q24) in
combination with a corresponding chromosome 8 α -satellite probe to evaluate genetic alterations in 8 primary melanomas and 33 advanced
melanomas and compared it to 12 melanocytic nevi, 7 safety margins and 2 cases of normal skin. Additionally, in metaphase spreads of 7
melanoma cell lines a whole chromosome 8 paint probe was used. We investigated the functionality of the c-myc gene by detecting c-myc
RNA expression with RT-PCR and c-myc protein by immunohistochemistry. 4/8 primary melanomas and 11/33 melanoma metastases
showed additional c-myc signals relative to the centromere of chromosome 8 copy number. None of the nevi, safety margins or normal skin
samples demonstrated this gain. In 2/7 melanoma cell lines (C32 and WM 266–4) isochromosome 8q formation with a relative gain of c-myc
copies and a loss of 8p was observed. The highest c-myc gene expression compared to GAPDH was found in melanoma metastases
(17.5%). Nevi (6.6%) and primary melanomas (5.0%) expressed the c-myc gene on a lower level. 72.7% of the patients with c-myc extra
copies had visceral melanoma metastases (UICC IV), patients without c-myc gain in 35.0% only. The collective with additional c-myc copies
also expressed the gene on a significantly higher level. These results indicate that a c-myc gain in relation to the centromere 8 copy number
might be associated with advanced cutaneous melanoma. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: c-myc; chromosome 8; fluorescence in situ hybridization; RT-PCR 
72
Received 10 April 2000 
Revised 24 August 2000 
Accepted 25 August 2000 
Correspondence to: GM Kraehn
British Journal of Cancer (2001) 84(1), 72–79
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2000.1535, available online at http://www.idealibrary.com on 
*G.M.K. and J.U. contributed equally to this work
http://www.bjcancer.comc-myc oncogene in malignant melanoma 73
British Journal of Cancer (2001) 84(1), 72–79 © 2001 Cancer Research Campaign
paraformaldehyde in 1 × PBS for 20 minutes, washed in 3× PBS,
1 × PBS, 1 × PBS (5 min each) and then dehydrated in ethanol
(30%, 60%, 80%, 95%, 100%). Touch preparations were stained
for S100 protein after standard protocols (DAKO, Germany) to
confirm presence of tumour cells. In cases where cryoconserved
tissue was available, the tumour material was chopped up and used
for FISH cell preparations and simultaneously for isolation of
RNA. The formalin-fixed parts of the tumours were sliced into 5
µ m sections and stained for S100 and c-myc protein. Each slice
was examined by two independent histopathologists. 
FISH 
The method of interphase FISH was used as described elsewhere
(Jenkins et al, 1997). Short time formalin fixed touch preparations
of the specimens were incubated in 2 × SSC at 75˚C for 15 min,
digested in pepsin solution (4 mg ml–1 in 0.9% NaCl, pH 1.5) for
15 min at 37˚C, rinsed in 2× SSC at room temperature for 5 min
and air dried. We used directly labelled fluorescent DNA probes
(Vysis, Downers Grove, IL, USA) for the centromere region of
chromosome 8 (CEP 8) and for the 8q24 (c-myc) region. Dual
probe hybridization was performed on the pretreated touch prepa-
rations using a spectrum green labelled centromere 8 probe in
combination with a spectrum orange labelled probe for c-myc
gene. Probes and target DNA were denatured simultaneously in a
78˚C oven for 4 min and each slide was incubated at 42˚C
overnight. Posthybridization washes were performed in 1.5 M
Urea/0.1× SSC at 45˚C for 30 min and in 2 × SSC at room temper-
ature for 2 min. Nuclei were counterstained with 4′ ,6-diamidino-2-
phenylindole and antifade compound p-phenylenediamine. We
used a fluorescence microscope (Zeiss, Germany) equipped with a
digital camera connected to a computer with Mc Probe software
(PSI, England) for analysis. Only signals in non-overlapping,
apparently intact nuclei (n = 100) were counted. An increased
copy number for the centromere of chromosome 8 and the c-myc
gene was defined as more than two signals in >10% of nuclei.
Gain of the c-myc signal in relation to centromere 8 was defined as
>25% of nuclei showing extra c-myc copies due to the fact that
chromatid separation in proliferative cells results in an apparent
increase in the number of signals located at distal parts of chromo-
somes (Hopman et al, 1994). The range of c-myc extra copies in
relation to centromere 8 is indicated as a ratio calculated as x = c-
myc signals per centromere 8 signals in all nuclei of the case. A c-
myc/centromere 8 ratio of >1 indicates a relative c-myc gain if
extra c-myc copies in relation to centromere 8 copy number are
detected in >25% of nuclei. 
RNA isolation and c-myc RT-PCR 
For RNA isolation the tissue was minced, homogenized, and RNA
was isolated from homogenates using the RNA-CleanTM System
(Angewandte Gentechnologie Systeme GmbH, Germany). Using
oligo (dt) primers the extracted mRNA was transcribed to 
cDNA with a Reverse Transcriptase System (Promega, Madison,
WI, USA) to cDNA. The cDNAs were then phenol/chloroform
extracted, precipitated with ethanol and redissolved in ddH2O. The
cDNA concentration was measured by reading the absorbance at
260 nm. In PCR reactions (25 µ l) 100 ng cDNA was used as
template-DNA. For semiquantitative analysis of the expression
level and to circumvent false negative results, we used primers
detecting the GAPDH gene in the same reaction vessel. The PCR
mixture contained, for each reaction, PCR-buffer, 1.5 mM Mg2+,
0.2 mM each dNTP, 1.7 U Taq polymerase (Boehringer,
Mannheim, Germany), 0.5 µ M c-myc upstream primer (Stra-
tagene, Heidelberg, Germany; 5′ CCAGCAGCGACTCTGAGG-
3′ ), 0.5 µ M c-myc downstream primer (5′ CCAAGACGTTGTG-
TGTTC 3′ ), 0.5 µ M GAPDH upstream primer (Stratagene
5′ CCACCCATGGCAAATTCCATGGCA 3′ ), 0.5 µ M GAPDH
downstream primer (5′ TCTAGACGGCAGGTCAGGTCCACC-
3′ ) and 100 ng cDNA. PCR consisted of an initial denaturation
step (94˚C 4 min), 30 amplification cycles (93˚C 35 sec, 60˚C 35
sec, 72˚C 35 sec) and a final extension step (68˚C 10 min). It was
tested that PCR was still in the exponential phase at the end of
cycling. The PCR products were visualized on a 2% agarose gel
stained with ethidium bromide. Contamination of cDNAs with
genomic DNA was ruled out by using intron-spanning primer sets.
Densitometric analysis of c-myc and GAPDH bands was
performed with a gel documentation system (Image Master VDS,
Pharmacia, Freiburg, Germany). The PCR product was sequenced
and the c-myc expression was calculated by setting the GAPDH
expression as 100% and setting the c-myc expression in relation to
this internal standard. 
Immunostaining of c-myc protein 
4 µ m sections were cut from paraffin blocks and were incubated in
xylene and ethanol. The tissue sections were microwaved for 7
min in 0.01 M sodium citrate buffer, pH 6.0 and incubated with
serum block for 20 min. Then sections were incubated with 2.5
µ g/ml mouse anti-human c-myc monoclonal antibody (9E10,
Santa Cruz, Heidelberg, Germany) for 2 hours at room tempera-
ture. Biotinylated secondary antibody was applied for 30 min.
After washing in PBS, HRP-streptavidin complex was placed on
the sections for 30 minutes and HRP substrate was added for 5
min. PBS instead of the primary antibody was used for negative
controls. The intensity of cytoplasmic immunostaining was scored
as negative, 1+, 2+ and 3+ for tumour cells corresponding to very
pale staining, light brown staining and dark brown staining. As a
positive control a melanoma tissue section known to express c-
myc protein was immunostained. 
Cell lines 
Metaphase spreads of the melanoma cell lines C 32, HT 144,
RPMI 7951, SK MEL 2, SK MEL 28, SK MEL 31, WM 266–4
(American Type Culture Collection, Rockville, USA) were
obtained by standard protocols. FISH with a whole chromosome
painting (WCP) probe for chromosome 8, a centromere 8 and a c-
myc probe (Vysis, Downers Grove, IL) was performed according
to the manufacturer’s instructions. 20 metaphase spreads of each
cell line were analysed and 100 interphase nuclei were counted for
c-myc and centromere of chromosome 8 copies. RNA was isolated
from each cell line at 3 different passages. Isolation of RNA and
PCR were performed as described above. 
RESULTS 
Fluorescence in situ hybridization 
FISH was performed on all 33 cutaneous melanoma metastases, 
8 primary melanomas, 12 nevi, 7 safety margins, 2 specimen of
normal skin from healthy donors and 7 melanoma cell lines. Melanoma cell lines 
All 7 cell lines showed extra copies of c-myc oncogene in combi-
nation with the centromere 8 copy number detected by FISH
(results are summarized in Table 1). Two cell lines (C 32 and WM
266–4) showed 8q isochromosome formation with a loss of 8p
(Figure 1). Only one metaphase spread of the amelanotic mela-
noma cell line C 32 revealed an 8q isochromosome and an 8p
isochromosome in addition to a normal chromosome 8 as detected
by inverted DAPI-banding. In all 7 cases no chromosome 8 
material was translocated to other chromosomes. 
Benign controls, safety margins and normal skin 
As expected normal skin from healthy donors showed no signal
gain. None of the 12 nevi showed extra copies of c-myc in relation
to chromosome 8 copy number. Nuclei of 2 nevi demonstrated in
10% and 17% 3 respectively 4 chromosomes 8. Safety margins of
cutaneous melanomas revealed no gain of chromosome 8 and c-
myc copies in 4/6 specimens. One case was observed to have 3
chromosomes 8 in 10% nuclei. The second safety margin showed
2 signals for centromere 8 and 3 signals for c-myc gene locus in
14% of the nuclei. 
Primary malignant melanomas 
The mean age of patients with primary melanoma was 71.8 years
(median 72.5 years). 5 patients were male and 3 were female. 4 of
the 8 primary malignant melanomas (see Table 2) were nodular
malignant melanomas (NMMs) showing a high mean Breslow
index of 7.61 mm (superficial spreading melanomas (SSMs) 
mean Breslow Index was 0.86 mm). All these NMM cases had a 
c-myc gain in relation to centromere 8 (Figure 2) while the other 
4 cases which were different histological subtypes (1 lentigo
maligna melanoma (LMM) and 3 SSMs) with lower tumour 
thickness showed no c-myc extra copies. NMMs had a c-myc/
centromere 8 ratio ranging from 1.20 to 2.84. Touch preparations
of these NMMs demonstrated extra c-myc copies relative to the
number of centromere 8 signals in 43%, 49%, 65% and 99%
nuclei. Case 3 and 5 showed a c-myc increase in association with
centromere 8 copy number. 
Advanced malignant melanomas 
Patients with advanced malignant melanoma ranged in age from
17 to 87 years (mean 60.4 years; median, 59 years). The samples
were collected from 17 women and 16 men. Of the 33 samples
tested, 30 cases showed centromere 8 and c-myc gain. C-myc
extra copies in relation to centromere 8 were found in 11 cases (4
lymph node metastases and 7 distant cutaneous metastases) (see
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Table 1 Chromosome 8 and c-myc copies in melanoma cell lines 
Cell line no. c-myc Nuclei with  c-myc/ Probe Percentage of nuclei with number of signals
RNA with  extra CEP  8
expression c-myc copies ratio 0–1 2 3 4 5 6 7 8 >9 
C 32 25.2 88% 1.30 c-myc 18 32 32 12 4 2
CEP 8a 18 24 52 2 2 2 
WM 266–4 19.1 92% 1.31 c-myc 2 88 8 1 1
CEP 8 3 84 11 2
HT 144 15.8 1% 0.95 c-myc 3 73  18 1 5
CEP 8 1 65 26 2 5 1
RPMI 7951 6.8 4% 0.95 c-myc 2 60  32 4 2
CEP 8 50 44 6
SK MEL 2 11.5 2% 0.89 c-myc 18 54 12 16
CEP 8 2 70 2 26
SK MEL 28 18.5 2% 1.00 c-myc 6  76 15 1 2 
CEP 8 4 73 21 1 1 
SK MEL 31 0 3% 0.90 c-myc 1 11 36  30 15 3 1 1 2 
CEP 8 36 33 18 8 2 1  2 
aCentromere of chromosome 8. 
Figure 1 Isochromosome 8q formation. The metaphase spread of the
amelanotic melanoma cell line C32 shows isochromosome 8q formation with
a relative gain of c-myc copies (orange signals: c-myc oncogene (8q24);
green signals: centromere of chromosome 8). The interphase nucleus
demonstrates 4 c-myc signals versus 3 centromere of chromosome 8 signals Table 3). C-myc/ centromere 8 ratio in those cases ranged from
1.22 to 2.90. Only case 26 showed one signal for centromere 8
with a c-myc gain (Figure 3) while the other specimens with c-
myc extra copies had 2 and more signals for centromere 8. 3/11
(27.3%) patients with extra c-myc in relation to centromere 8
had cutaneous or lymph node metastases, whereas 8/11 (72.7%)
patients revealed visceral metastases (including lung, bone,
suprarenal, liver, peritoneal, spleen and cerebral metastases). In
contrast to this collective, patients with balanced numbers of c-
myc copies and centromere 8 had cutaneous or lymph node
metastases in 65% (13/20) versus 35% (7/20) with visceral
metastases (lung, cerebral, suprarenal, liver, bone) (see Figure
4). In both groups similar results for the Breslow index (mean
3.95 mm, median 1.85 mm with extra copies versus mean 
2.76 mm, median 2.4 mm without additional c-myc copies) were
found. 
RT-PCR 
The amplified products of c-myc and GAPDH mRNA were
detected as 345 bp and 598 bp fragments. 6/7 cell lines showed c-
myc expression (data shown in Table 1). The highest c-myc RNA
level in relation to GAPDH was found in those cell lines with
isochromosome 8q formation (C32 mean 25.2% and WM 266–4
mean 19.1%). Melanoma metastases had the highest expression of
the c-myc gene relative to GAPDH (mean 17.5%, median 16.9%).
A similar level of c-myc mRNA was found in primary melanoma
(mean 5.0%, median 2.15%) and in nevi (mean 6.62%, median
5.3%). In a single case of lentigo maligna a high c-myc expression
comparable to those of metastases was detected (21.8%). Normal
skin of healthy donors showed an average expression of 1.4%.
Safety margins of melanomas had an expression of 4.2%. In one
NMM (case no 8) a 3-fold excess could be detected in the tumour
compared to the c-myc expression levels in the safety margin by
RT-PCR. This tumour demonstrated additional c-myc gene copies
in relation to the centromere 8 copy number. 
Immunostaining 
To confirm the results on chromosomal and RNA level immuno-
staining with monoclonal antibody was performed on 25 sections.
Nuclear and cytoplasmic staining for c-myc was found in 70% of all
investigated melanoma metastases. An elevated c-myc expression
was detected in those patients with the c-myc extra copies on the
DNA level. In this group only one case was negative for c-myc
staining. This group showed an average staining of 1.63+ (versus
0.66+ in the collective without additional c-myc copies). No signifi-
cant difference of c-myc expression was found between nevi (53.8%
positive) and primary cutaneous melanomas (60.0% positive). 
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Table 2 Chromosome 8 and c-myc copies in primary malignant melanomas 
Case Diagnosis/tumour c-myc  Nuclei with c-myc/ Probe Percent of nuclei with number of signals
no. thickness  RNA- extra c- CEP 8
expression myc copies ratio 0–1 23456 7 8 > 9  
1 SSM 0.8 mm 2.0 8% 0.92 c-myc  16 72 6 4 2
CEP 8a 4 8 8422
2 SSM 0.75 mm 1% 1.03 c-myc 5  87 2 6
CEP 8 8 81 5 6
3 SSM 1.04 mm 4.0 1% 0.93 c-myc  3 80 15 2
CEP 8 3 67 25 4 1
4 NMM 11.0 mm 14.7 49% 1.30 c-myc  2 49 29 12 6 1 1
CEP 8 1 90 4 5
5 LMM not determined 9% 0.95 c-myc 7  32 31 27 2 1
CEP 8 3 45 10 36 4 1 1 
6 NMM 2.1 mm 43% 1.43 c-myc 2  39 25 17 7 7 1 2
CEP 8 4 78 7 11
7 NMM 12.1 mm 2.0 65% 1.20 c-myc  2 12 6 7 20 24 22 7
CEP 8 1 14 10 16 38 19 2
8 NMM 5.25 mm 2.3 99% 2.84 c-myc  1 18 28 28 17 6 2 
CEP 8 2 96 2
aCentromere of chromosome 8. 
Figure 2 C-myc amplification: Dual-probe FISH with a centromere 8 probe
(green) and a region specific probe for c-myc gene (orange) showing a
nucleus with c-myc extra copies in relation to centromere 8 and a normal
nucleus in a touch preparation of a nodular malignant melanoma (case 8) 76 GM Kraehn et al
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Table 3 Chromosome 8 and c-myc copies in melanoma metastases 
Case Diagnosis c-myc  Nuclei c-myc/ Probe Percent of nuclei with number of signals
no. (primary tumour,   RNA- with CEP 8
tumour expression extra c- ratio
thickness) myc copies 0–1 2 3 4 5 6 7 8 >9 
9 metastasis (MMa, not determined) 4% 0.92 c-myc 24 74 2
CEP 8b 14 86
10 metastasis (NMM, 8.0 mm) 2% 0.97  c-myc 12 82 4 2
CEP 8 7 87 4 2
11 metastasis (NMM, 2.75 mm) 5.0 6% 0.95 c-myc 20 68 8 2 2
CEP 8 5 89 2 2 2
12 metastasis (SSM, 5.0 mm) 13.0 5% 1.03 c-myc 1 95 4
CEP 8 3 96 1
13 metastasis (NMM, 1.2 mm) 12% 1.04  c-myc 10 80 8 2
CEP 8 7 92 1
14 metastasis (SSM, 0.96 mm) 10% 1.09  c-myc 2 88 6 2 2
CEP 8 7 93
15 metastasis (MM, not determined) 6% 0.97  c-myc 5 79 12 4
CEP 8 2 83 9 6 
16 metastasis (SSM, 2.76 mm) 16% 1.11  c-myc 3 81 10 4 2
CEP 8 4 96
17 metastasis (NMM, 2.3 mm) 22.3 12% 1.06 c-myc 9 73 10 6 2
CEP 8 8 82 4 6
18 metastasis (MM on nevus) 28% 1.23 c-myc 8 64 20 6 2
CEP 8 11 86 2 1
19 metastasis (MM on nevus) 29% 1.24 c-myc 2 70 13 8 4 1 1 1 
CEP 8 3 93 1 2 1
20 metastasis (LMM, 14.0 mm) 63% 1.31  c-myc 3 67 11 8 7 2 1 1
CEP 8 2 96 1 1
21 metastasis (SSM, 2.2 mm) 54% 1.32  c-myc 4 40 46 6 2 2
CEP 8 3 91 4 2
22 metastasis (NMM, 2.05 mm) 2% 0.98  c-myc 1 16 81 2
CEP 8 13 85 2
23 metastasis (SSM, 1.69 mm) 21% 1.13  c-myc 2 54 17 19 5 1 1 1 
CEP 8 3 72 5 17 1 1 1 
24 metastasis (SSM, 0.9 mm) 13% 1.07  c-myc 22 69 3 2 4
CEP 8 26 72 1 1
25 metastasis (MM, not determined) 10% 1.04  c-myc 8 84 2 2 4
CEP 8 1 14 79 2 2 2
26 metastasis (SSM, 1.5 mm) 91% 2.90  c-myc 2 8 61 26 1 2
CEP 8 91 8 1
27 metastasis (ALM, not determined) 8% 1.05  c-myc 1 8 71 13 1 6
CEP 8 15 72 8 2 3
28 metastasis (NMM, 1.5 mm) 5.5 1% 0.93 c-myc 2 24 30 36 4 2 2 
CEP 8 22 12 56 8 2
29 metastasis (ALM, 3.3 mm) 18.4 10% 1.01 c-myc 10 43 44 2 1
CEP 8 1 13 41 42 1 1 1
30 metastasis (NMM, 3.3 mm) 24.6 64% 1.66 c-myc 2 27 25 26 13 5 1 1 
CEP 8 5 80 13 2
31 metastasis (MM, not determined) 9.3 6% 1.00 c-myc 1 23 10 58 8
CEP 8 24 9 63 4
32 metastasis (ALM, 0.74 mm) 39.1 65% 1.30 c-myc 14 18 53 12 1 2 
CEP 8 21 70 7 1 1
33 metastasis (NMM, 3.5 mm) 21% 1.05  c-myc 1 9 7 75 5 1 2 
CEP 8 10 22 64 2 2
34 metastasis (MM, not determined) 16% 1.08  c-myc 1 9 10 60 8 2 8 2
CEP 8 1 9 16 66 2 4 2
35 metastasis (NMM, 2.4 mm) 13% 1.05  c-myc 4 25 1 24 23 6 5 3 9 
CEP 8 1 25 2 32 29 1 1 2  7 
36 metastasis (SSM, 1.4 mm) 47% 1.22  c-myc 1 2 4 51 14 21 3 3 1 
CEP 8 4 11 83 1 1
37 metastasis (MM, not determined) 51% 1.32  c-myc 14 8 23 22 17 7 6 3 
CEP 8 2 31 13 26 12 15 1 
38 metastasis (SSM, 3.15 mm) 17% 0.98  c-myc 2 4 5 11 30 27 17 2 2 
CEP 8 5 2 11 28 47 4 3 
39 metastasis (MM, not determined) 15.9 8% 0.94 c-myc 1 5 2 10 33 34 4 9  2 
CEP 8 3 4 2 5 36 36 1 5  8 
40 metastasis (ALM, 7.36 mm) 79% 1.42  c-myc 1 3 10 20 21 18 8 19 
CEP 8 1 10 45 32 2 1 6  3 
41 metastasis (SSM, 1.13 mm) 22.2 96% 1.59 c-myc 2 4 17 65 12 
CEP 8 2 2 9 85 2
aMalignant melanoma. bCentromere of chromosome 8. c-myc oncogene in malignant melanoma 77
British Journal of Cancer (2001) 84(1), 72–79 © 2001 Cancer Research Campaign
DISCUSSION 
Myc family oncoproteins have been demonstrated to be sequence-
specific transcription factors that are believed to regulate the
expression of genes governing cellular growth, differentiation, and
programmed cell death (Chin et al, 1996; Thompson, 1998). 
We report on c-myc gene extra copies and their relationship 
to centromere of chromosome 8 copy number in primary and
advanced malignant melanoma in comparison to normal skin and
benign nevi. One factor contributing to additional c-myc gene
copies in tumour cells is non-polyploid gain of whole chromosome
8. Additional 8q arms or isochromosome 8q formation is another
factor. Gain of 8q has been detected in posterior uveal melanoma
by FISH (Sisley et al, 1997) and by CGH (Ghazvini et al, 1996).
Our results of metaphase spreads of cutaneous melanoma cell lines
showed isochromosome 8q formation in two cell lines. Thus we
hypothesize that the observed intermediate relative increase in c-
myc is caused by isochromes 8q. Homogeneously staining regions
(hsr) and double minute chromosomes (dmin) are regarded as hall-
marks of gene amplification which might be the basis for high c-
myc expression (gene-dose-effect). 
Furthermore, chromatid separation in highly proliferative cells
results in an apparent intermediate increase in the number of c-
myc signals while the number of centromere 8 signals remains
constant during the cell cycle stages (Hopman et al, 1994). It may
be estimated that c-myc signal gain in up to 25% of counted nuclei
might reflect the proliferative activity. 
C-myc oncogene extra copies related to centromere 8 in >25%
of nuclei were found in 4/8 primary melanomas (Table 2) and in
11/33 melanoma metastases (Table 3). All benign control cases
failed to show c-myc extra copies in relation to centromere 8. Our
data suggest that additional c-myc gene copies and overexpres-
sion of c-myc – isolated or combined with other genes mapped to
8q – may play an important role in the progression of malignant
melanoma. The high number of patients at an advanced stage of
the disease with visceral metastases that had a c-myc copy
number gain in relation to chromosome 8, in contrast to a rela-
tively unaltered situation predominantly found in patients with
cutaneous and lymph node metastases, is a striking result. A
similar situation was found in SCID mice. Here, subcutaneous
injection of a transfected melanoma cell line with high c-myc
expression resulted in a more aggressive growth behaviour with
lymph node and lung metastases compared to a cell line with
lower c-myc expression (Schlagbauer-Wadl et al, 1999). Similar
data exist in breast cancer where c-myc amplification is corre-
lated with an aggressive clinical behaviour (Berns et al, 1992) or
in colorectal cancer where c-myc amplification (Masramon et al,
1998) and c-myc mRNA expression assessed by RT-PCR
(Kakisako et al, 1998) are indicative of a shorter disease-free
survival. 
In our cases the highest c-myc expression levels have been
detected by RT-PCR in advanced melanomas, in contrast to rela-
tively low levels in primary tumours and nevi. Our results both on
RNA and protein level confirm published data showing similar c-
myc expression on the protein level in primary melanoma and in
nevi (Bergman et al, 1997) and a higher expression in melanoma
metastases (Grover et al, 1996). Regarding the relation of c-myc
expression to the number of c-myc FISH signals, nevi and a subset
of primary tumours with a tumour thickness up to 1.04 mm have
both a combination of low expression and low signal number,
whereas primary melanomas with a high tumour thickness (5.2
mm; 11.0 mm; 12.1 mm) have either an elevated expression or a
higher number of signals (Table 2, Figure 5). Metastases show an
even more pronounced pattern: elevated expression, elevated gene
copy number or a combination of both features (Figure 5). These
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observations suggest a mechanism that involves transcription as
well as polysomy in the progression of the disease. 
From a clinical point of view 2 patients with metastases and
additional c-myc copies had a low tumour thickness of the primary
tumour (case 32: 0.74 mm and case 41: 1.13 mm). Based upon
epidemiological data (Balch et al, 1985) this low tumour thickness
would predict a benign course of the disease. The aggressive clin-
ical behaviour of these two melanomas is in obvious contrast to the
epidemiological data. C-myc extra copies might offer an explana-
tion for this unexpected tumour progression in these 2 patients. C-
myc copy number may also reflect a surrogate marker for genetic
instability. The predominance of c-myc expression on RNA and
protein level in metastases, associated with increased c-myc copy
number in relation to centromere of chromosome 8 number, argues
for the involvement of c-myc in late stage malignant melanoma.
The data presented certainly warrant further prospective studies to
elucidate the role of extra c-myc copies in relation to centromere 8
copy number as a genetic alteration reflecting the stage of the
disease. 
Findings of additional c-myc copies in combination with the
centromere 8 copy number in one safety margin and 1 extra c-myc
signal in relation to the centromere 8 copy number in 14% of
nuclei in another safety margin is an interesting observation. This
might be either caused by inapparent tumour cells or, more likely,
by a high proliferative state of the normal tissue. Due to a two step
excisional procedure of the primary melanoma fibrotic or inflam-
matory processes in the safety margin might result in a highly
proliferative status, which could explain the alteration of the rela-
tive increase of the c-myc copy number in relation to the
centromere 8 number. Alteration of gene expression and chromo-
somal aberration might help to determine the appropriate safety
margin for melanoma in the future. 
Additionally, based on the observation of down-modulation of 
c-myc expression by interferon γ in human melanoma cell lines
(Osanto et al, 1992) and the enhancement of the efficacy of
cisplatin in melanoma chemotherapy by c-myc antisense
oligodeoxynucleotides both in vitro and in nude mice (Citro et al,
1998), c-myc expression in relation to chromosome 8 copy number
might open new ways to identify patients with an increased chance
to benefit from certain chemotherapeutic regimens. 
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